• R&D expenditure increased in 2007 and reached a record amount of EUR 1.137 billion
• Investments in fixed assets were as great as in 2006 (EUR 152 million
• Sales and operating profits decreased

Beerse, 27 May 2008 – Today Janssen Pharmaceutica organized, in presence of Koen Geens, head of the cabinet of Kris Peeters, Minister-President of the Flemish government, the planting of a maypole in the new pilot plant, the roof of which is nearly finished. The plant is the largest investment the company has ever made and will be operational by 2011. The factory acts as a bridge between the research division and production. It will be responsible for producing medicines for clinical research and for “scaling up” production processes, in order to determine whether the synthesis of new molecules in a laboratory environment can also be applied on an industrial scale.

Paul Stoffels, Company Group Chairman of Johnson & Johnson Pharmaceutical Research & Development, gave an overview of the group’s future prospects: “We still have some difficult years ahead of us, but we also hold the future in our own hands. The knowledge and efforts of our staff is our greatest asset. We will now concentrate these fully on our core activities: discovering, developing, manufacturing and selling new medicines. We have all the necessary technology in-house to progress. We will also develop our cooperation with other partners further.”

• R&D expenditure increased in 2007 and reached a record amount of EUR 1.137 billion
• Investments in fixed assets were as great as in 2006 (EUR 152 million
• Sales and operating profits decreased

Beerse, 27 May 2008 – Today Janssen Pharmaceutica organized, in presence of Koen Geens, head of the cabinet of Kris Peeters, Minister-President of the Flemish government, the planting of a maypole in the new pilot plant, the roof of which is nearly finished. The plant is the largest investment the company has ever made and will be operational by 2011. The factory acts as a bridge between the research division and production. It will be responsible for producing medicines for clinical research and for “scaling up” production processes, in order to determine whether the synthesis of new molecules in a laboratory environment can also be applied on an industrial scale.

Paul Stoffels, Company Group Chairman of Johnson & Johnson Pharmaceutical Research & Development, gave an overview of the group’s future prospects: “We still have some difficult years ahead of us, but we also hold the future in our own hands. The knowledge and efforts of our staff is our greatest asset. We will now concentrate these fully on our core activities: discovering, developing, manufacturing and selling new medicines. We have all the necessary technology in-house to progress. We will also develop our cooperation with other partners further.”